Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Expected to Post Q2 2024 Earnings of ($0.77) Per Share

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Investment analysts at Capital One Financial decreased their Q2 2024 earnings per share estimates for Day One Biopharmaceuticals in a research report issued on Tuesday, May 7th. Capital One Financial analyst N. Quibria now expects that the company will post earnings per share of ($0.77) for the quarter, down from their prior estimate of ($0.71). The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. Capital One Financial also issued estimates for Day One Biopharmaceuticals’ Q3 2024 earnings at ($0.73) EPS, Q4 2024 earnings at ($0.68) EPS, FY2024 earnings at ($2.90) EPS, FY2025 earnings at ($2.47) EPS, FY2026 earnings at ($1.29) EPS, FY2027 earnings at ($0.17) EPS and FY2028 earnings at $0.83 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07).

Several other equities analysts have also recently weighed in on the company. JPMorgan Chase & Co. lifted their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday, April 22nd. The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. HC Wainwright lowered their price target on shares of Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday. Finally, Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Day One Biopharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Day One Biopharmaceuticals Trading Down 3.9 %

Shares of DAWN stock opened at $16.41 on Thursday. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -6.89 and a beta of -1.44. Day One Biopharmaceuticals has a 1-year low of $9.67 and a 1-year high of $18.07. The stock’s fifty day simple moving average is $15.46 and its 200-day simple moving average is $14.19.

Insider Transactions at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Jeremy Bender sold 70,051 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $17.88, for a total transaction of $1,252,511.88. Following the completion of the transaction, the chief executive officer now directly owns 651,762 shares in the company, valued at $11,653,504.56. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the sale, the insider now owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 195,247 shares of company stock worth $3,376,817. 8.40% of the stock is owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 130.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after buying an additional 1,262 shares during the period. Quest Partners LLC bought a new stake in shares of Day One Biopharmaceuticals in the 4th quarter worth approximately $29,000. Quintet Private Bank Europe S.A. grew its holdings in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares in the last quarter. Amalgamated Bank increased its position in shares of Day One Biopharmaceuticals by 35.7% during the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after purchasing an additional 2,268 shares during the period. Finally, Exchange Traded Concepts LLC raised its stake in shares of Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after purchasing an additional 2,554 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.